Envoy Medical, Inc. (NASDAQ: COCH) disclosed a notable insider purchase and related equity instruments in a Form 4 filing with the Securities and Exchange Commission. On February 12, 2026, Interim Chief Financial Officer Robert Potashnick acquired 212,500 shares of Class A Common Stock at $0.40 per share, for a total transaction value of $85,000.
In the same filing, Potashnick reported receiving warrants to purchase 340,000 shares of Class A Common Stock, each exercisable at a price of $0.40 per share. In addition to the shares and warrants, Potashnick holds options to purchase 15,000 shares of Class A Common Stock at an exercise price of $0.53. Those options include a vesting schedule that begins on February 5, 2027.
Separately, Envoy Medical announced progress in its clinical development program for the investigational Acclaim cochlear implant. The company said it has reached the midway point of enrollment in its pivotal study and expects full enrollment to be completed within the first half of the first quarter of 2026. Envoy noted that progress has continued despite holiday scheduling challenges and that multiple study sites are actively screening candidates.
Envoy also reported a recent intellectual property milestone. An Australian patent was issued on October 16, 2025, covering innovations intended to improve the signal-to-noise ratio in cochlear implant systems. The patent description references an input source with a sensor and a powered signal modifier that includes an amplifier as elements covered by the granted patent.
Taken together, the SEC filing and corporate updates outline the current positioning of Envoy Medical from both a capital-holding and development perspective. The insider purchase, the suite of warrants and options, the reported enrollment progress in the Acclaim pivotal study, and the Australian patent comprise the set of developments formally disclosed by the company.
Contextual note - The company filings and corporate statements cited above are the basis for this report. The information on share purchases, warrants, option terms, enrollment status, and the patent issuance are drawn from the disclosed regulatory filing and the company announcements referenced in that filing.